Cargando…
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
AIMS: Heart failure (HF) is a common co‐morbidity in non‐valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time‐in‐therapeutic range with warfarin. We assessed the real‐world effectiveness and safety of rivaroxaban and warfarin in NVAF patien...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352884/ https://www.ncbi.nlm.nih.gov/pubmed/30299591 http://dx.doi.org/10.1002/ehf2.12365 |